September 24, 2021 at 08:05PM CUVITRU

Product approval information is indicated for replacement therapy for primary humoral immunodeficiency (PI) in adult and pediatric patients two years of age and older.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/2WJ3mKO